Cargando…
Advances in antiangiogenic treatment of small-cell lung cancer
Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell...
Autores principales: | Lu, Hongyang, Jiang, Zhiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238765/ https://www.ncbi.nlm.nih.gov/pubmed/28138259 http://dx.doi.org/10.2147/OTT.S119714 |
Ejemplares similares
-
Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011) -
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond
por: Gori, Bruno, et al.
Publicado: (2011) -
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
por: He, Danming, et al.
Publicado: (2023) -
Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort
por: Wang, Zeng, et al.
Publicado: (2019) -
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
por: González, Alicia, et al.
Publicado: (2021)